Clinical Trial Update: A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough [Phase 3]

View source ↗

Summary

A 52-week Phase 3 trial evaluating the efficacy and safety of BLU-5937 in adults with refractory chronic cough has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• BLU-5937 (BLU-5937)

Snippet

Sponsor: Bellus Health Inc. - a GSK company | Conditions: Cough, Refractory Chronic Cough | Phase 3 | Status: COMPLETED